Articles tagged "Prophylaxis"

2019 American Transplant Congress
Spontaneous Bacterial Peritonitis Prophylaxis Increases the Risk of Multi-Drug Resistant Cultures and Infections in Liver Transplant Patients
R. Rosenblatt, A. Schluger, M. Pereira, E. Verna
Columbia University Medical Center, New York, NY
*Purpose: Spontaneous bacterial peritonitis prophylaxis (SBP-P) is increasingly prescribed to patients awaiting liver transplantation (LT), but its impact on multidrug resistant organisms (MDRO) or the…
2019 American Transplant Congress
Effect of Enoxaparin Prophylaxis on Early VTE Post Lung Transplant
S. Marshall¹, K. Tsveybel¹, S. Boukedes¹, P. Burkett², R. Chepuri², A. Coppolino³, M. Divo², S. El-Chemaly², S. Keller², J. Kennedy², H. Mallidi³, G. Mody³, T. Thaniyavarn², A. Trindade², K. Townsend¹, H. Goldberg²
¹Lung Transplant, Brigham & Women's Hospital, Boston, MA, ²Pulmonary Division, Brigham & Women's Hospital, Boston, MA, ³Thoracic Surgery, Brigham & Women's Hospital, Boston, MA
*Purpose: Thromboembolic complications are common post-transplant leading to significant morbidity. We instituted early enoxaparin prophylaxis (ppx) in lung transplant recipients (LTR) due to an observed…
2019 American Transplant Congress
Risk Stratification of Cytomegalovirus Seropositive Kidney Transplant Recipients for CMV Infection
M. M. Azar¹, A. Baghban¹, K. Belfield¹, R. Assi², M. Malinis¹
¹Yale University, New Haven, CT, ²University of Pennsylvania, Philadelphia, PA
*Purpose: Current consensus guidelines for CMV prevention recommend valganciclovir (VGCV) prophylaxis for 3 months after transplantation for CMV R+ kidney transplant recipients (KTR). This standard…
2019 American Transplant Congress
Anti-Fungal Prophylaxis in Lung Transplant: A Systematic Review/Meta-Analysis
K. Pennington, M. Baqir, P. Erwin, H. Murad, R. Razonable, C. C. Kennedy
Mayo Clinic, Rochester, MN
*Purpose: Invasive fungal infections (IFI) increase morbidity and mortality after lung transplant. Despite this, anti-fungal prophylaxis (AFP) in lung transplant recipients (LTR) varies by prophylactic…
2019 American Transplant Congress
Use of a CMV Specific T Cell Immunity Assay in Late-Onset CMV Infection
O. Beaird¹, M. Carlson¹, P. Gaynor¹, D. Nanayakkara¹, B. Abdalla², S. Bunnapradist², J. Schaenman¹
¹Department of Internal Medicine - Division Infectious Diseases, UCLA, Los Angeles, CA, ²Department of Internal Medicine - Division Nephrology, UCLA, Los Angeles, CA
*Purpose: To describe our clinical experience using a CMV Specific Cell Mediated Immunity (CMI) assay in solid organ transplant (SOT) recipients with late-onset CMV, defined…
2019 American Transplant Congress
Retrospective Evaluation of Optimal Cmv Prophylaxis Regimens in Lung Transplant Patients: Analysis of Patient Outcomes Pre and Post Protocol Dosing Alterations
J. Hunt, A. Nasar, R. Walia, L. Cherrier
St. Joseph Hospital and Medical Center, Phoenix, AZ
*Purpose: Given the heightened risk of cytomegalovirus (CMV) following lung transplantation compared to other solid organ transplants, with minimal evidence based guidance specific to this…
2019 American Transplant Congress
Experience With Letermovir Use For The Management Of Cytomegalovirus In Solid Organ Transplant Recipients
J. L. Orejas¹, F. M. Marty¹, A. M. McDonnell², M. P. Cheng¹, E. Arbona-Haddad¹, S. P. Hammond¹, S. Koo¹
¹Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, ²Department of Pharmacy, Brigham and Women's Hospital, Boston, MA
*Purpose: Letermovir is a new antiviral recently approved for cytomegalovirus (CMV) prophylaxis in CMV-seropositive hematopoietic-cell transplant recipients. Its off-label use in solid organ transplant (SOT)…
2019 American Transplant Congress
Incidence of Cytomegalovirus in Moderate Risk Kidney Transplant Recipients Receiving Low Dose Valganciclovir
T. Fallah¹, A. Logan², L. Beltran Garcia³, L. Bowman²
¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²Tampa General Hospital, Tampa, FL, ³Florida Kidney Physicians, Tampa General Hospital, Tampa, FL
*Purpose: Studies evaluating the efficacy of valganciclovir (VGC) at 450 mg daily versus 900 mg daily for the prevention of cytomegalovirus (CMV) in kidney transplant…
2019 American Transplant Congress
Target Itraconazole Trough Concentration for Prophylaxis in Lung Transplant
J. A. Morillas-Rodriguez¹, H. Hassouna², F. Marco-Canosa³, K. D. Brizendine¹
¹Infectious disease, Cleveland Clinic, Cleveland, OH, ²Infectious disease, Spectrum health, Grand rapids, MI, ³Cleveland Clinic, Cleveland, OH
*Purpose: Itraconazole (ITR) therapeutic drug monitoring (TDM) for prophylaxis in lung transplant recipients (LTR) is not well characterized. Our purpose was to evaluate ITR trough…
2019 American Transplant Congress
Outbreak of Pneumocystis Pneumonia in a Transplant Center Linked to a Single Genotype of Pneumocystis jirovecii: Effects of Cytomegalovirus Infection and Allograft Rejection
S. Hosseini-Moghaddam¹, S. Dufresne², M. Shokoohi³, G. Singh¹, E. HunterGutierrez¹, P. Dufresne², A. House¹, P. Luke¹, A. Nagpal¹, P. Marotta¹, A. Humar⁴, A. Jevnikar¹, D. Kumar⁴
¹Western University,LHSC,University Hospital, London, ON, Canada, ²Maisonneuve-Rosemont Hospital,Université de Montréal, Montreal, QC, Canada, ³Epidemiology and Biostatistics, Western University, London, ON, Canada, ⁴University of Toronto, University Health Network, Toronto General Hospital, Toronto, ON, Canada
*Purpose: Although post-transplant pneumocystis pneumonia (PCP) outbreaks have been reported from Asia, Australia and Europe, there are limited data from North America. We investigated transmissibility…

« Previous Page
1
…
6
7
8
9
10
…
14
Next Page »